200 related articles for article (PubMed ID: 23778521)
1. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer.
Shen Y; Wang P; Li Y; Ye F; Wang F; Wan X; Cheng X; Lu W; Xie X
Br J Cancer; 2013 Jul; 109(1):92-9. PubMed ID: 23778521
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel.
Lin F; Wang P; Shen Y; Xie X
Eur J Gynaecol Oncol; 2015; 36(4):432-6. PubMed ID: 26390698
[TBL] [Abstract][Full Text] [Related]
3. miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT.
Shen Y; Zhou J; Li Y; Ye F; Wan X; Lu W; Xie X; Cheng X
PLoS One; 2014; 9(10):e109299. PubMed ID: 25330011
[TBL] [Abstract][Full Text] [Related]
4. MiR-509-3p Induces Apoptosis and Affects the Chemosensitivity of Cervical Cancer Cells by Targeting the RAC1/PAK1/LIMK1/Cofilin Pathway.
Xu J; Ma X; Yang H; Zhang J; Cai G; Yao N
Chem Pharm Bull (Tokyo); 2021; 69(4):325-332. PubMed ID: 33790078
[TBL] [Abstract][Full Text] [Related]
5. MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer.
Li J; Ping Z; Ning H
Int J Mol Sci; 2012 Nov; 13(12):16053-64. PubMed ID: 23443110
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
7. MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.
Chen L; Cao H; Feng Y
World J Urol; 2018 Mar; 36(3):357-365. PubMed ID: 29204706
[TBL] [Abstract][Full Text] [Related]
8. miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression.
Xu X; Jin S; Ma Y; Fan Z; Yan Z; Li W; Song Q; You W; Lyu Z; Song Y; Shi P; Liu Y; Han X; Li L; Li Y; Liu Y; Ye Q
J Mol Med (Berl); 2017 Aug; 95(8):861-871. PubMed ID: 28487996
[TBL] [Abstract][Full Text] [Related]
9. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
11. BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer.
Sugio A; Iwasaki M; Habata S; Mariya T; Suzuki M; Osogami H; Tamate M; Tanaka R; Saito T
Gynecol Oncol; 2014 Sep; 134(3):615-23. PubMed ID: 24992675
[TBL] [Abstract][Full Text] [Related]
12. MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo.
Peng X; Cao P; He D; Han S; Zhou J; Tan G; Li W; Yu F; Yu J; Li Z; Cao K
Int J Clin Exp Pathol; 2014; 7(10):6784-91. PubMed ID: 25400759
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-138 is a potential biomarker and tumor suppressor in human cervical carcinoma by reversely correlated with TCF3 gene.
Li H; Sheng Y; Zhang Y; Gao N; Deng X; Sheng X
Gynecol Oncol; 2017 Jun; 145(3):569-576. PubMed ID: 28385388
[TBL] [Abstract][Full Text] [Related]
14. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-mediated miR-29b expression inhibits the invasion and angiogenesis of cervical cancer.
Li Y; Zhang Z; Xiao Z; Lin Y; Luo T; Zhou Q; Zhang X
Oncotarget; 2017 Feb; 8(9):14655-14665. PubMed ID: 28122338
[TBL] [Abstract][Full Text] [Related]
17. WNT1, a target of miR-34a, promotes cervical squamous cell carcinoma proliferation and invasion by induction of an E-P cadherin switch via the WNT/β-catenin pathway.
Li B; Guo X; Li N; Chen Q; Shen J; Huang X; Huang G; Wang F
Cell Oncol (Dordr); 2020 Jun; 43(3):489-503. PubMed ID: 32301035
[TBL] [Abstract][Full Text] [Related]
18. Clusterin confers paclitaxel resistance in cervical cancer.
Park DC; Yeo SG; Shin EY; Mok SC; Kim DH
Gynecol Oncol; 2006 Dec; 103(3):996-1000. PubMed ID: 16890274
[TBL] [Abstract][Full Text] [Related]
19. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1.
Chen J; Li G
Biomed Pharmacother; 2018 Nov; 107():997-1003. PubMed ID: 30257412
[TBL] [Abstract][Full Text] [Related]
20. Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.
Chen N; Chon HS; Xiong Y; Marchion DC; Judson PL; Hakam A; Gonzalez-Bosquet J; Permuth-Wey J; Wenham RM; Apte SM; Cheng JQ; Sellers TA; Lancaster JM
Oncol Rep; 2014 Jan; 31(1):376-83. PubMed ID: 24220856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
